2 papers2 findings
GLP-1 receptor agonists
no changein humans1HR 0.71
GLP-1 receptor agonists have no effect on fatal stroke in humans (HR 0.71; 0.47–1.07).
“No statistically significant effect on fatal stroke was observed (HR 0.71; 0.47–1.07; based on three trials).”
Human trialtype 2 diabetes
Targeting Cerebrovascular Risk in Diabetes: GLP-1 Receptor Agonists as Neuroprotective Agents
AHA Scientific Sessions 2025 abstract3 Nov 2025
Antihypertensive treatment
downin humans1−33%
Antihypertensive treatment lowers the risk of fatal stroke in humans (-33%).
“The incidence of fatal stroke was reduced by 33%”
Reviewhypertension
Treatment of hypertension in the elderly
Journal of hypertension1 Jun 1995
Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.